The Business of Biotech 2.0 is here, and to say you’re getting an upgrade is a giant understatement. If you haven’t tuned in to episode 247 (dropped on 3/31), give it a listen and meet your new host! Ben Comer has been Chief Editor at Life Science Leader for the past 3 years, was Executive Editor at In Vivo for a few years before that, spent five and a half years with PwC’s Health Research Institute, served as Senior Editor at Pharmaceutical Executive magazine for three and a half years, and wrote for Haymarket Media’s medical group before that. He’s long been a student of the space, he's a genuinely great guy, and he’s tooled up to take the podcast well into the future. From now on, tune in to the videocast here at Life Science Leader.
For my part, I’m taking on some new responsibilities here at Life Science Connect. It might sound cliché, but it truly is bittersweet. Spending these hundreds of hours with the brilliant human beings that are the living, breathing fountainheads of biotech innovation has been a highlight of my career. The only thing cooler than that has been hearing from the listeners impacted and informed by all these episodes. Thank you to the entire community.
As always, thanks for watching and listening, and rest assured that you’re in better hands with Ben! Now, here's this month's hand-picked content from around the horn at Life Science Connect.
Matt Pillar, VP, Editorial & Content, Life Science Connect and former host, the Business of Biotech podcast |
|
| | Biotech Beat | April 22, 2025 |
|
| ![]() | | by JESSICA MENG | No, not "most valuable player. In this Life Science Leader exclusive, CareDx Chief Commercial officer and former Genentech marketing head for Avastin Jessica Meng compares drug marketing to the software industry, making the case for taking your "minimum viable product" commercial, then strategizing product improvement and indication expansion. | READ NOW → |
|
![]() | | by TYLER MENICHIELLO | On April 22 at 11 AM, we'll host a Bioprocess Online Live panel on continuous versus batch manufacturing. It's an old argument, constantly injected with new wrinkles. Join us for it, and in the meantime, warm up with this report from Bioprocess Online's man on the street, Tyler Menichiello, who caught up with AstraZeneca's Ken Lee at BPI West in San Diego last month. | READ NOW → |
|
| ![]() | | by ERIN HARRIS | Speaking of live panel events, Cell & Gene's Erin Harris hosted one last month that covered some emerging cell therapy manufacturing technologies. Here's a recap, featuring Arcellx Head of Manufacturing & MSAT Rohit Ingale and Vor Bio VP/Head of Manufacturing David O’Donnell waxing on high throughput, robotics, advanced analytics, and more. | READ NOW → |
|
![]() | | by LOUIS GARGUILO | I'll admit that I saw this headline shortly after making the mistake of glancing at my investment portfolio. "What if it works for who?" I scoffed. But, ever the devil's advocate, Outsourced Pharma's Louis Garguilo takes a stab at some "what if" scenarios for biopharma in these early days of the Trump Tariffs. Read what's sure to be the first of many columns on the topic here. | READ NOW → |
|
| | "I'm excited a lot by the format because it scratches various itches that I have in learning about people through profiles, and exploring all sorts of different issues, whether they're regulatory or policy related or commercial related." | ― Ben Comer, Chief Editor, Life Science Leader and Host, Business of Biotech podcast, Episode 247 |
|
| "We've now ignored R&D investment in some of the larger opportunities, and frankly, the obesity space and some of the GLP1 successes in obesity that have opened people's eyes to the fact that there really is still a lot of unmet need in some of these primary care segments." | ― Nima Farzan, CEO, Latigo Biotherapeutics, Episode 246 |
|
| "We've brought together a consortium of 11 companies, the founding members of QurAlis, Stoke Therapeutics, Avidity Biosciences, Ultragenyx, and others to really try to catalyze changes and work with the FDA to see if we can build more of a risk-benefit approach into the regulatory pathway." | ― Kasper Roet. Ph.D., CEO, QurAlis, Episode 245 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Stay versed in all things biotech - developments, products, services, and the individuals setting the pace. The Life Science Connect community offers its subscribers an assemblage of resources from discerning editorial to interactive webinars, entertaining podcasts to supplier white papers, and more. |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
